Company Announcements

Barclays US LLC 2020 CCAR results

Source: RNS
RNS Number : 2044R
Barclays PLC
26 June 2020
 

 

 

25 June 2020

Barclays PLC

 

Barclays US LLC receives non-objection to its capital plan in 2020 CCAR

 

Barclays notes the Board of Governors of the Federal Reserve's ("FRB") publication of the 2020 Dodd-Frank Act Stress Test ("DFAST") and Comprehensive Capital Analysis and Review ("CCAR") results for Barclays US LLC (Barclays' US Intermediate Holding Company, the "IHC"), on 25 June 2020.

 

The FRB did not object to Barclays US LLC's capital plan, and under both the FRB's and Barclays' company-run assessment of the supervisory severely adverse scenario, the IHC's projected capital ratios remained above regulatory minimum required levels across all nine quarters of the test.

 

Barclays US LLC today published its own assessment of the supervisory severely adverse scenario, which can be found on the Barclays website at: https://home.barclays/investor-relations/investor-news/fed-filings/ 

 

 

Ends

 

 

For further information please contact:

 

Investor Relations

Media Relations

Chris Manners

Tom Hoskin

+44 (0) 20 7773 2136

 +44 (0) 20 7116 6927

 

Laura Vallis

+1 212 526 3514

 

About Barclays

Barclays is a British universal bank. We are diversified by business, by different types of customer

and client, and geography. Our businesses include consumer banking and payments operations

around the world, as well as a top-tier, full service, global corporate and investment bank, all of

which are supported by our service company which provides technology, operations and functional

services across the Group.

 

For further information about Barclays, please visit our website home.barclays  

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCQQLBLBQLXBBE